M. Berge

Safe Management of Tacrolimus Together With Posaconazole in Lung Transplant Patients With Cystic Fibrosis

R. Guillemain, C. Amrein, E. Billaud, 2009, Therapeutic drug monitoring.

Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.

R. Guillemain, A. L. Louët, C. Amrein, 2010, Medical mycology.

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients

M. Loriot, R. Guillemain, A. L. Louët, 2009, Transplant infectious disease : an official journal of the Transplantation Society.

Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients

D. Tregouet, M. Loriot, P. Beaune, 2011, European Journal of Clinical Pharmacology.

[Level of evidence for therapeutic drug monitoring of posaconazole].

E. Billaud, C. L. Le Guellec, S. Lefeuvre, 2011, Therapie.

Management of Metabolic Cytochrome P450 3A4 Drug-Drug Interaction between Everolimus and Azole Antifungals in a Renal Transplant Patient

C. Antoine, D. Glotz, M. Benammar, 2009, Clinical drug investigation.

Neuromuscular painful disorders: a rare side effect of voriconazole in lung transplant patients under tacrolimus.

R. Guillemain, A. L. Louët, C. Beller, 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.

R. Guillemain, A. L. Louët, C. Amrein, 2010, Medical mycology.